母胎医学会咨询系列#57:妊娠中期孤立性软指标评估与管理(替代咨询#10、#16、#17、#25、#27)
母胎医学会发布咨询系列#57,讨论在当前母血清筛查和无细胞DNA筛查背景下,妊娠中期超声发现的孤立性软指标(定义:无胎儿结构异常、生长受限或其他软指标)的评估与管理。指南共提出13条推荐,涵盖心内强回声灶、肠管回声增强、泌尿系统扩张、股骨/肱骨缩短、颈褶增厚、鼻骨缺失/发育不良、脉络丛囊肿和单脐动脉等,多数推荐等级为GRADE 1B或1C。
要点
- 孤立性心内强回声灶或脉络丛囊肿在血清/无细胞DNA筛查阴性时无需进一步评估,属正常变异。
- 孤立性肠管回声增强需评估囊性纤维化和胎儿巨细胞病毒感染,并建议晚孕期超声复查。
- 孤立性单脐动脉无需额外非整倍体评估,建议晚孕期超声评估生长,可考虑自36 0/7周起每周产前胎儿监护。
核心结论
- 母胎医学会针对妊娠中期孤立性软指标提出13条推荐:血清或无细胞DNA筛查阴性时,孤立性心内强回声灶、脉络丛囊肿无需进一步评估;孤立性肠管回声增强需评估囊性纤维化和巨细胞病毒感染;孤立性单脐动脉无需非整倍体评估但需晚孕期超声;孤立性泌尿系统扩张A1型建议≥32周超声,A2-3型个体化随访。
研究设计与样本
- 母胎医学会咨询系列文件,替代既往5份咨询文件(#10单脐动脉、#16孤立性肠管回声增强、#17孤立性肾盂扩张、#25孤立性胎儿脉络丛囊肿、#27孤立性心内强回声灶),基于当前母血清筛查和无细胞DNA筛查选项提出推荐,采用GRADE分级。
关键影像表现/征象
- 孤立性定义为详细产科超声检查后未发现胎儿结构异常、生长受限或其他软指标。
- 血清筛查方法包括早孕期筛查、整合筛查、序贯筛查、 contingent筛查或四联筛查。
- 孤立性心内强回声灶和孤立性脉络丛囊肿被视为无临床重要性的正常变异。
诊断标准与关键数值
- 无既往非整倍体筛查且孤立性心内强回声灶、肠管回声增强、泌尿系统扩张或肱骨/股骨缩短:建议咨询估计21三体概率并讨论无创筛查(无细胞DNA或四联筛查)(GRADE 1B)。
- 无既往筛查且孤立性颈褶增厚或鼻骨缺失/发育不良:建议咨询估计21三体概率并讨论无创筛查或羊膜腔穿刺诊断(GRADE 1B)。
- 无既往筛查且孤立性脉络丛囊肿:建议咨询估计18三体概率并讨论无创筛查(GRADE 1C)。
- 血清或无细胞DNA筛查阴性且孤立性心内强回声灶或脉络丛囊肿:不建议进一步评估(GRADE 1B/1C)。
- 血清筛查阴性且孤立性颈褶增厚或鼻骨缺失/发育不良:建议咨询并讨论不再评估、无细胞DNA筛查或羊膜腔穿刺(GRADE 1B);无细胞DNA阴性则不建议进一步评估(GRADE 1B)。
临床应用与阅片要点
- 血清或无细胞DNA筛查阴性时,孤立性心内强回声灶无需胎儿超声心动图、随访超声或出生后评估(GRADE 1B)。
- 孤立性肠管回声增强需评估囊性纤维化和胎儿巨细胞病毒感染,并建议晚孕期超声重新评估和生长评价(GRADE 1C)。
- 孤立性单脐动脉无论既往筛查低风险或拒绝检测,均不建议额外非整倍体评估;建议晚孕期超声评估生长,可考虑自36 0/7周起每周产前胎儿监护(GRADE 1C)。
- 孤立性泌尿系统扩张A1型建议≥32周超声以确定是否需要出生后小儿泌尿科或肾内科随访;A2-3型建议个体化随访超声并计划出生后随访(GRADE 1C)。
- 孤立性肱骨/股骨缩短建议晚孕期超声重新评估和生长评价(GRADE 1C)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Soft markers were originally introduced to prenatal ultrasonography to improve the detection of trisomy 21 over that achievable with age-based and serum screening strategies. As prenatal genetic screening strategies have greatly evolved in the last 2 decades, the relative importance of soft markers has shifted. The purpose of this document is to discuss the recommended evaluation and management of isolated soft markers in the context of current maternal serum screening and cell-free DNA screening options. In this document, "isolated" is used to describe a soft marker that has been identified in the absence of any fetal structural anomaly, growth restriction, or additional soft marker following a detailed obstetrical ultrasound examination. In this document, "serum screening methods" refers to all maternal screening strategies, including first-trimester screen, integrated screen, sequential screen, contingent screen, or quad screen. The Society for Maternal-Fetal Medicine recommends the following approach to the evaluation and management of isolated soft markers: (1) we do not recommend diagnostic testing for aneuploidy solely for the evaluation of an isolated soft marker following a negative serum or cell-free DNA screening result (GRADE 1B); (2) for pregnant people with no previous aneuploidy screening and isolated echogenic intracardiac focus, echogenic bowel, urinary tract dilation, or shortened humerus, femur, or both, we recommend counseling to estimate the probability of trisomy 21 and a discussion of options for noninvasive aneuploidy screening with cell-free DNA or quad screen if cell-free DNA is unavailable or cost-prohibitive (GRADE 1B); (3) for pregnant people with no previous aneuploidy screening and isolated thickened nuchal fold or isolated absent or hypoplastic nasal bone, we recommend counseling to estimate the probability of trisomy 21 and a discussion of options for noninvasive aneuploidy screening through cell-free DNA or quad screen if cell-free DNA is unavailable or cost-prohibitive or diagnostic testing via amniocentesis, depending on clinical circumstances and patient preference (GRADE 1B); (4) for pregnant people with no previous aneuploidy screening and isolated choroid plexus cysts, we recommend counseling to estimate the probability of trisomy 18 and a discussion of options for noninvasive aneuploidy screening with cell-free DNA or quad screen if cell-free DNA is unavailable or cost-prohibitive (GRADE 1C); (5) for pregnant people with negative serum or cell-free DNA screening results and an isolated echogenic intracardiac focus, we recommend no further evaluation as this finding is a normal variant of no clinical importance with no indication for fetal echocardiography, follow-up ultrasound imaging, or postnatal evaluation (GRADE 1B); (6) for pregnant people with negative serum or cell-free DNA screening results and isolated fetal echogenic bowel, urinary tract dilation, or shortened humerus, femur, or both, we recommend no further aneuploidy evaluation (GRADE 1B); (7) for pregnant people with negative serum screening results and isolated thickened nuchal fold or absent or hypoplastic nasal bone, we recommend counseling to estimate the probability of trisomy 21 and discussion of options for no further aneuploidy evaluation, noninvasive aneuploidy screening through cell-free DNA, or diagnostic testing via amniocentesis, depending on clinical circumstances and patient preference (GRADE 1B); (8) for pregnant people with negative cell-free DNA screening results and isolated thickened nuchal fold or absent or hypoplastic nasal bone, we recommend no further aneuploidy evaluation (GRADE 1B); (9) for pregnant people with negative serum or cell-free DNA screening results and isolated choroid plexus cysts, we recommend no further aneuploidy evaluation, as this finding is a normal variant of no clinical importance with no indication for follow-up ultrasound imaging or postnatal evaluation (GRADE 1C); (10) for fetuses with isolated echogenic bowel, we recommend an evaluation for cystic fibrosis and fetal cytomegalovirus infection and a third-trimester ultrasound examination for reassessment and evaluation of growth (GRADE 1C); (11) for fetuses with an isolated single umbilical artery, we recommend no additional evaluation for aneuploidy, regardless of whether results of previous aneuploidy screening were low risk or testing was declined. We recommend a third-trimester ultrasound examination to evaluate growth and consideration of weekly antenatal fetal surveillance beginning at 36 0/7 weeks of gestation (GRADE 1C); (12) for fetuses with isolated urinary tract dilation A1, we recommend an ultrasound examination at ≥32 weeks of gestation to determine if postnatal pediatric urology or nephrology follow-up is needed. For fetuses with urinary tract dilation A2-3, we recommend an individualized follow-up ultrasound assessment with planned postnatal follow-up (GRADE 1C); (13) for fetuses with isolated shortened humerus, femur, or both, we recommend a third-trimester ultrasound examination for reassessment and evaluation of growth (GRADE 1C).
引用
- Prabhu M, Kuller JA, Biggio JR, et al. Society for Maternal-Fetal Medicine Consult Series #57: Evaluation and management of isolated soft ultrasound markers for aneuploidy in the second trimester: (Replaces Consults #10, Single umbilical artery, October 2010; #16, Isolated echogenic bowel diagnosed on second-trimester ultrasound, August 2011; #17, Evaluation and management of isolated renal pelviectasis on second-trimester ultrasound, December 2011; #25, Isolated fetal choroid plexus cysts, April 2013; #27, Isolated echogenic intracardiac focus, August 2013). Am J Obstet Gynecol. 2021. PMID: 34171388. doi:10.1016/j.ajog.2021.06.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。